Combining Valosin-containing Protein (VCP) Inhibition and Suberanilohydroxamic Acid (SAHA) Treatment Additively Enhances the Folding, Trafficking, and Function of Epilepsy-associated γ-Aminobutyric Acid, Type A (GABAA) Receptors
GABAA receptors are the primary inhibitory ion channels in the mammalian central nervous system. The A322D mutation in the α1 subunit results in its excessive endoplasmic reticulum-associated degradation at the expense of plasma membrane trafficking, leading to autosomal dominant juvenile myoclonic...
Gespeichert in:
Veröffentlicht in: | The Journal of biological chemistry 2015-01, Vol.290 (1), p.325-337 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 337 |
---|---|
container_issue | 1 |
container_start_page | 325 |
container_title | The Journal of biological chemistry |
container_volume | 290 |
creator | Han, Dong-Yun Di, Xiao-Jing Fu, Yan-Lin Mu, Ting-Wei |
description | GABAA receptors are the primary inhibitory ion channels in the mammalian central nervous system. The A322D mutation in the α1 subunit results in its excessive endoplasmic reticulum-associated degradation at the expense of plasma membrane trafficking, leading to autosomal dominant juvenile myoclonic epilepsy. Presumably, valosin-containing protein (VCP)/p97 extracts misfolded subunits from the endoplasmic reticulum membrane to the cytosolic proteasome for degradation. Here we showed that inhibiting VCP using Eeyarestatin I reduces the endoplasmic reticulum-associated degradation of the α1(A322D) subunit without an apparent effect on its dynamin-1 dependent endocytosis and that this treatment enhances its trafficking. Furthermore, coapplication of Eeyarestatin I and suberanilohydroxamic acid, a known small molecule that promotes chaperone-assisted folding, yields an additive restoration of surface expression of α1(A322D) subunits in HEK293 cells and neuronal SH-SY5Y cells. Consequently, this combination significantly increases GABA-induced chloride currents in whole-cell patch clamping experiments than either chemical compound alone in HEK293 cells. Our findings suggest that VCP inhibition without stress induction, together with folding enhancement, represents a new strategy to restore proteostasis of misfolding-prone GABAA receptors and, therefore, a potential remedy for idiopathic epilepsy.The α1 subunit harboring the A322D mutation is subject to excessive ERAD.
VCP inhibition using Eeyarestatin I reduces the ERAD of α1(A322D) subunits, and coapplication of SAHA additively enhances their proteostasis.
Combining ERAD inhibition and folding enhancement yields significant functional rescue.
This combination represents a new, promising strategy to treat epilepsy resulting from GABAA receptor misfolding. |
doi_str_mv | 10.1074/jbc.M114.580324 |
format | Article |
fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4281735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925820579325</els_id><sourcerecordid>S0021925820579325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-95067da0359e2eadd713198fbcc1f9a9fb61f9d68f7efa5cb6f82f00a6a6187e3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhSMEokNhzQ55OZXI1M5_NkjpaKatVERFS8XOcuzrjktiR7Zn1DxX34O34D3wNKWCBd5c-frc7_jqRNF7ghcEl9nxXcsXnwnJFnmF0yR7Ec0IrtI4zcn3l9EM44TEdZJXB9Eb5-5wOFlNXkcHSZ7hIiXZLPq1NH2rtNK36IZ1xikdc6M9m1qX1nhQGs1vlpdH6FxvVKu8MhoxLdDVtgXLtOrMZhTW3LNecdRwJdD8qjlrjtC1BeZ70B41QoS5HXQjWukN0xwc8htAa9OJ4PMxSJmUiv94vOzh663mj05GotWgOhjcGDPnDFfMg0A_H-KmV9q0Wz_aJ9-AGQdADZqfNidN-MBX4DB4Y93b6JVknYN3T_Uw-rZeXS_P4osvp-fL5iLmWZb6uM5xUQqG07yGBJgQJUlJXcmWcyJrVsu2CFUUlSxBspy3hawSiTErWEGqEtLD6NPEHbZtD4KH3S3r6GBVz-xIDVP03xetNvTW7GiWVKRM8wA4ngDcGucsyOdZguk-cRoSp_vE6ZR4mPjwt-Wz_k_EQVBPAgiL7xRY6riCEIFQFrinwqj_wn8DfbLAig</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combining Valosin-containing Protein (VCP) Inhibition and Suberanilohydroxamic Acid (SAHA) Treatment Additively Enhances the Folding, Trafficking, and Function of Epilepsy-associated γ-Aminobutyric Acid, Type A (GABAA) Receptors</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Han, Dong-Yun ; Di, Xiao-Jing ; Fu, Yan-Lin ; Mu, Ting-Wei</creator><creatorcontrib>Han, Dong-Yun ; Di, Xiao-Jing ; Fu, Yan-Lin ; Mu, Ting-Wei</creatorcontrib><description>GABAA receptors are the primary inhibitory ion channels in the mammalian central nervous system. The A322D mutation in the α1 subunit results in its excessive endoplasmic reticulum-associated degradation at the expense of plasma membrane trafficking, leading to autosomal dominant juvenile myoclonic epilepsy. Presumably, valosin-containing protein (VCP)/p97 extracts misfolded subunits from the endoplasmic reticulum membrane to the cytosolic proteasome for degradation. Here we showed that inhibiting VCP using Eeyarestatin I reduces the endoplasmic reticulum-associated degradation of the α1(A322D) subunit without an apparent effect on its dynamin-1 dependent endocytosis and that this treatment enhances its trafficking. Furthermore, coapplication of Eeyarestatin I and suberanilohydroxamic acid, a known small molecule that promotes chaperone-assisted folding, yields an additive restoration of surface expression of α1(A322D) subunits in HEK293 cells and neuronal SH-SY5Y cells. Consequently, this combination significantly increases GABA-induced chloride currents in whole-cell patch clamping experiments than either chemical compound alone in HEK293 cells. Our findings suggest that VCP inhibition without stress induction, together with folding enhancement, represents a new strategy to restore proteostasis of misfolding-prone GABAA receptors and, therefore, a potential remedy for idiopathic epilepsy.The α1 subunit harboring the A322D mutation is subject to excessive ERAD.
VCP inhibition using Eeyarestatin I reduces the ERAD of α1(A322D) subunits, and coapplication of SAHA additively enhances their proteostasis.
Combining ERAD inhibition and folding enhancement yields significant functional rescue.
This combination represents a new, promising strategy to treat epilepsy resulting from GABAA receptor misfolding.</description><identifier>ISSN: 0021-9258</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1074/jbc.M114.580324</identifier><identifier>PMID: 25406314</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Action Potentials - drug effects ; Action Potentials - physiology ; Adenosine Triphosphatases - antagonists & inhibitors ; Adenosine Triphosphatases - genetics ; Adenosine Triphosphatases - metabolism ; Adolescent ; Cell Cycle Proteins - antagonists & inhibitors ; Cell Cycle Proteins - genetics ; Cell Cycle Proteins - metabolism ; Cell Line, Tumor ; Chlorides - metabolism ; Drug Synergism ; Dynamin I - genetics ; Dynamin I - metabolism ; Endocytosis - drug effects ; Endoplasmic Reticulum - drug effects ; Endoplasmic Reticulum - metabolism ; Endoplasmic Reticulum-Associated Degradation - drug effects ; Endoplasmic Reticulum-Associated Degradation - genetics ; Epilepsy ; ER Quality Control ; ER-associated Degradation ; GABA Receptor ; gamma-Aminobutyric Acid - metabolism ; HEK293 Cells ; Humans ; Hydrazones - pharmacology ; Hydroxamic Acids - pharmacology ; Hydroxyurea - analogs & derivatives ; Hydroxyurea - pharmacology ; Myoclonic Epilepsy, Juvenile - genetics ; Myoclonic Epilepsy, Juvenile - metabolism ; Myoclonic Epilepsy, Juvenile - pathology ; Neurons - drug effects ; Neurons - metabolism ; Neurons - pathology ; Patch-Clamp Techniques ; Proteasome Endopeptidase Complex - drug effects ; Proteasome Endopeptidase Complex - metabolism ; Protein Folding - drug effects ; Protein Misfolding ; Protein Stability - drug effects ; Protein Synthesis and Degradation ; Proteostasis ; Receptors, GABA-A - chemistry ; Receptors, GABA-A - genetics ; Receptors, GABA-A - metabolism ; SAHA ; Signal Transduction ; Valosin Containing Protein ; VCP ; Vorinostat</subject><ispartof>The Journal of biological chemistry, 2015-01, Vol.290 (1), p.325-337</ispartof><rights>2015 © 2015 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.</rights><rights>2015 by The American Society for Biochemistry and Molecular Biology, Inc.</rights><rights>2015 by The American Society for Biochemistry and Molecular Biology, Inc. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-95067da0359e2eadd713198fbcc1f9a9fb61f9d68f7efa5cb6f82f00a6a6187e3</citedby><cites>FETCH-LOGICAL-c443t-95067da0359e2eadd713198fbcc1f9a9fb61f9d68f7efa5cb6f82f00a6a6187e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281735/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281735/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27915,27916,53782,53784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25406314$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Han, Dong-Yun</creatorcontrib><creatorcontrib>Di, Xiao-Jing</creatorcontrib><creatorcontrib>Fu, Yan-Lin</creatorcontrib><creatorcontrib>Mu, Ting-Wei</creatorcontrib><title>Combining Valosin-containing Protein (VCP) Inhibition and Suberanilohydroxamic Acid (SAHA) Treatment Additively Enhances the Folding, Trafficking, and Function of Epilepsy-associated γ-Aminobutyric Acid, Type A (GABAA) Receptors</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>GABAA receptors are the primary inhibitory ion channels in the mammalian central nervous system. The A322D mutation in the α1 subunit results in its excessive endoplasmic reticulum-associated degradation at the expense of plasma membrane trafficking, leading to autosomal dominant juvenile myoclonic epilepsy. Presumably, valosin-containing protein (VCP)/p97 extracts misfolded subunits from the endoplasmic reticulum membrane to the cytosolic proteasome for degradation. Here we showed that inhibiting VCP using Eeyarestatin I reduces the endoplasmic reticulum-associated degradation of the α1(A322D) subunit without an apparent effect on its dynamin-1 dependent endocytosis and that this treatment enhances its trafficking. Furthermore, coapplication of Eeyarestatin I and suberanilohydroxamic acid, a known small molecule that promotes chaperone-assisted folding, yields an additive restoration of surface expression of α1(A322D) subunits in HEK293 cells and neuronal SH-SY5Y cells. Consequently, this combination significantly increases GABA-induced chloride currents in whole-cell patch clamping experiments than either chemical compound alone in HEK293 cells. Our findings suggest that VCP inhibition without stress induction, together with folding enhancement, represents a new strategy to restore proteostasis of misfolding-prone GABAA receptors and, therefore, a potential remedy for idiopathic epilepsy.The α1 subunit harboring the A322D mutation is subject to excessive ERAD.
VCP inhibition using Eeyarestatin I reduces the ERAD of α1(A322D) subunits, and coapplication of SAHA additively enhances their proteostasis.
Combining ERAD inhibition and folding enhancement yields significant functional rescue.
This combination represents a new, promising strategy to treat epilepsy resulting from GABAA receptor misfolding.</description><subject>Action Potentials - drug effects</subject><subject>Action Potentials - physiology</subject><subject>Adenosine Triphosphatases - antagonists & inhibitors</subject><subject>Adenosine Triphosphatases - genetics</subject><subject>Adenosine Triphosphatases - metabolism</subject><subject>Adolescent</subject><subject>Cell Cycle Proteins - antagonists & inhibitors</subject><subject>Cell Cycle Proteins - genetics</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Chlorides - metabolism</subject><subject>Drug Synergism</subject><subject>Dynamin I - genetics</subject><subject>Dynamin I - metabolism</subject><subject>Endocytosis - drug effects</subject><subject>Endoplasmic Reticulum - drug effects</subject><subject>Endoplasmic Reticulum - metabolism</subject><subject>Endoplasmic Reticulum-Associated Degradation - drug effects</subject><subject>Endoplasmic Reticulum-Associated Degradation - genetics</subject><subject>Epilepsy</subject><subject>ER Quality Control</subject><subject>ER-associated Degradation</subject><subject>GABA Receptor</subject><subject>gamma-Aminobutyric Acid - metabolism</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Hydrazones - pharmacology</subject><subject>Hydroxamic Acids - pharmacology</subject><subject>Hydroxyurea - analogs & derivatives</subject><subject>Hydroxyurea - pharmacology</subject><subject>Myoclonic Epilepsy, Juvenile - genetics</subject><subject>Myoclonic Epilepsy, Juvenile - metabolism</subject><subject>Myoclonic Epilepsy, Juvenile - pathology</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Neurons - pathology</subject><subject>Patch-Clamp Techniques</subject><subject>Proteasome Endopeptidase Complex - drug effects</subject><subject>Proteasome Endopeptidase Complex - metabolism</subject><subject>Protein Folding - drug effects</subject><subject>Protein Misfolding</subject><subject>Protein Stability - drug effects</subject><subject>Protein Synthesis and Degradation</subject><subject>Proteostasis</subject><subject>Receptors, GABA-A - chemistry</subject><subject>Receptors, GABA-A - genetics</subject><subject>Receptors, GABA-A - metabolism</subject><subject>SAHA</subject><subject>Signal Transduction</subject><subject>Valosin Containing Protein</subject><subject>VCP</subject><subject>Vorinostat</subject><issn>0021-9258</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhSMEokNhzQ55OZXI1M5_NkjpaKatVERFS8XOcuzrjktiR7Zn1DxX34O34D3wNKWCBd5c-frc7_jqRNF7ghcEl9nxXcsXnwnJFnmF0yR7Ec0IrtI4zcn3l9EM44TEdZJXB9Eb5-5wOFlNXkcHSZ7hIiXZLPq1NH2rtNK36IZ1xikdc6M9m1qX1nhQGs1vlpdH6FxvVKu8MhoxLdDVtgXLtOrMZhTW3LNecdRwJdD8qjlrjtC1BeZ70B41QoS5HXQjWukN0xwc8htAa9OJ4PMxSJmUiv94vOzh663mj05GotWgOhjcGDPnDFfMg0A_H-KmV9q0Wz_aJ9-AGQdADZqfNidN-MBX4DB4Y93b6JVknYN3T_Uw-rZeXS_P4osvp-fL5iLmWZb6uM5xUQqG07yGBJgQJUlJXcmWcyJrVsu2CFUUlSxBspy3hawSiTErWEGqEtLD6NPEHbZtD4KH3S3r6GBVz-xIDVP03xetNvTW7GiWVKRM8wA4ngDcGucsyOdZguk-cRoSp_vE6ZR4mPjwt-Wz_k_EQVBPAgiL7xRY6riCEIFQFrinwqj_wn8DfbLAig</recordid><startdate>20150102</startdate><enddate>20150102</enddate><creator>Han, Dong-Yun</creator><creator>Di, Xiao-Jing</creator><creator>Fu, Yan-Lin</creator><creator>Mu, Ting-Wei</creator><general>Elsevier Inc</general><general>American Society for Biochemistry and Molecular Biology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20150102</creationdate><title>Combining Valosin-containing Protein (VCP) Inhibition and Suberanilohydroxamic Acid (SAHA) Treatment Additively Enhances the Folding, Trafficking, and Function of Epilepsy-associated γ-Aminobutyric Acid, Type A (GABAA) Receptors</title><author>Han, Dong-Yun ; Di, Xiao-Jing ; Fu, Yan-Lin ; Mu, Ting-Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-95067da0359e2eadd713198fbcc1f9a9fb61f9d68f7efa5cb6f82f00a6a6187e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Action Potentials - drug effects</topic><topic>Action Potentials - physiology</topic><topic>Adenosine Triphosphatases - antagonists & inhibitors</topic><topic>Adenosine Triphosphatases - genetics</topic><topic>Adenosine Triphosphatases - metabolism</topic><topic>Adolescent</topic><topic>Cell Cycle Proteins - antagonists & inhibitors</topic><topic>Cell Cycle Proteins - genetics</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Chlorides - metabolism</topic><topic>Drug Synergism</topic><topic>Dynamin I - genetics</topic><topic>Dynamin I - metabolism</topic><topic>Endocytosis - drug effects</topic><topic>Endoplasmic Reticulum - drug effects</topic><topic>Endoplasmic Reticulum - metabolism</topic><topic>Endoplasmic Reticulum-Associated Degradation - drug effects</topic><topic>Endoplasmic Reticulum-Associated Degradation - genetics</topic><topic>Epilepsy</topic><topic>ER Quality Control</topic><topic>ER-associated Degradation</topic><topic>GABA Receptor</topic><topic>gamma-Aminobutyric Acid - metabolism</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Hydrazones - pharmacology</topic><topic>Hydroxamic Acids - pharmacology</topic><topic>Hydroxyurea - analogs & derivatives</topic><topic>Hydroxyurea - pharmacology</topic><topic>Myoclonic Epilepsy, Juvenile - genetics</topic><topic>Myoclonic Epilepsy, Juvenile - metabolism</topic><topic>Myoclonic Epilepsy, Juvenile - pathology</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Neurons - pathology</topic><topic>Patch-Clamp Techniques</topic><topic>Proteasome Endopeptidase Complex - drug effects</topic><topic>Proteasome Endopeptidase Complex - metabolism</topic><topic>Protein Folding - drug effects</topic><topic>Protein Misfolding</topic><topic>Protein Stability - drug effects</topic><topic>Protein Synthesis and Degradation</topic><topic>Proteostasis</topic><topic>Receptors, GABA-A - chemistry</topic><topic>Receptors, GABA-A - genetics</topic><topic>Receptors, GABA-A - metabolism</topic><topic>SAHA</topic><topic>Signal Transduction</topic><topic>Valosin Containing Protein</topic><topic>VCP</topic><topic>Vorinostat</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, Dong-Yun</creatorcontrib><creatorcontrib>Di, Xiao-Jing</creatorcontrib><creatorcontrib>Fu, Yan-Lin</creatorcontrib><creatorcontrib>Mu, Ting-Wei</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, Dong-Yun</au><au>Di, Xiao-Jing</au><au>Fu, Yan-Lin</au><au>Mu, Ting-Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combining Valosin-containing Protein (VCP) Inhibition and Suberanilohydroxamic Acid (SAHA) Treatment Additively Enhances the Folding, Trafficking, and Function of Epilepsy-associated γ-Aminobutyric Acid, Type A (GABAA) Receptors</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2015-01-02</date><risdate>2015</risdate><volume>290</volume><issue>1</issue><spage>325</spage><epage>337</epage><pages>325-337</pages><issn>0021-9258</issn><eissn>1083-351X</eissn><abstract>GABAA receptors are the primary inhibitory ion channels in the mammalian central nervous system. The A322D mutation in the α1 subunit results in its excessive endoplasmic reticulum-associated degradation at the expense of plasma membrane trafficking, leading to autosomal dominant juvenile myoclonic epilepsy. Presumably, valosin-containing protein (VCP)/p97 extracts misfolded subunits from the endoplasmic reticulum membrane to the cytosolic proteasome for degradation. Here we showed that inhibiting VCP using Eeyarestatin I reduces the endoplasmic reticulum-associated degradation of the α1(A322D) subunit without an apparent effect on its dynamin-1 dependent endocytosis and that this treatment enhances its trafficking. Furthermore, coapplication of Eeyarestatin I and suberanilohydroxamic acid, a known small molecule that promotes chaperone-assisted folding, yields an additive restoration of surface expression of α1(A322D) subunits in HEK293 cells and neuronal SH-SY5Y cells. Consequently, this combination significantly increases GABA-induced chloride currents in whole-cell patch clamping experiments than either chemical compound alone in HEK293 cells. Our findings suggest that VCP inhibition without stress induction, together with folding enhancement, represents a new strategy to restore proteostasis of misfolding-prone GABAA receptors and, therefore, a potential remedy for idiopathic epilepsy.The α1 subunit harboring the A322D mutation is subject to excessive ERAD.
VCP inhibition using Eeyarestatin I reduces the ERAD of α1(A322D) subunits, and coapplication of SAHA additively enhances their proteostasis.
Combining ERAD inhibition and folding enhancement yields significant functional rescue.
This combination represents a new, promising strategy to treat epilepsy resulting from GABAA receptor misfolding.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25406314</pmid><doi>10.1074/jbc.M114.580324</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9258 |
ispartof | The Journal of biological chemistry, 2015-01, Vol.290 (1), p.325-337 |
issn | 0021-9258 1083-351X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4281735 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Action Potentials - drug effects Action Potentials - physiology Adenosine Triphosphatases - antagonists & inhibitors Adenosine Triphosphatases - genetics Adenosine Triphosphatases - metabolism Adolescent Cell Cycle Proteins - antagonists & inhibitors Cell Cycle Proteins - genetics Cell Cycle Proteins - metabolism Cell Line, Tumor Chlorides - metabolism Drug Synergism Dynamin I - genetics Dynamin I - metabolism Endocytosis - drug effects Endoplasmic Reticulum - drug effects Endoplasmic Reticulum - metabolism Endoplasmic Reticulum-Associated Degradation - drug effects Endoplasmic Reticulum-Associated Degradation - genetics Epilepsy ER Quality Control ER-associated Degradation GABA Receptor gamma-Aminobutyric Acid - metabolism HEK293 Cells Humans Hydrazones - pharmacology Hydroxamic Acids - pharmacology Hydroxyurea - analogs & derivatives Hydroxyurea - pharmacology Myoclonic Epilepsy, Juvenile - genetics Myoclonic Epilepsy, Juvenile - metabolism Myoclonic Epilepsy, Juvenile - pathology Neurons - drug effects Neurons - metabolism Neurons - pathology Patch-Clamp Techniques Proteasome Endopeptidase Complex - drug effects Proteasome Endopeptidase Complex - metabolism Protein Folding - drug effects Protein Misfolding Protein Stability - drug effects Protein Synthesis and Degradation Proteostasis Receptors, GABA-A - chemistry Receptors, GABA-A - genetics Receptors, GABA-A - metabolism SAHA Signal Transduction Valosin Containing Protein VCP Vorinostat |
title | Combining Valosin-containing Protein (VCP) Inhibition and Suberanilohydroxamic Acid (SAHA) Treatment Additively Enhances the Folding, Trafficking, and Function of Epilepsy-associated γ-Aminobutyric Acid, Type A (GABAA) Receptors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T00%3A58%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combining%20Valosin-containing%20Protein%20(VCP)%20Inhibition%20and%20Suberanilohydroxamic%20Acid%20(SAHA)%20Treatment%20Additively%20Enhances%20the%20Folding,%20Trafficking,%20and%20Function%20of%20Epilepsy-associated%20%CE%B3-Aminobutyric%20Acid,%20Type%20A%20(GABAA)%20Receptors&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Han,%20Dong-Yun&rft.date=2015-01-02&rft.volume=290&rft.issue=1&rft.spage=325&rft.epage=337&rft.pages=325-337&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1074/jbc.M114.580324&rft_dat=%3Celsevier_pubme%3ES0021925820579325%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25406314&rft_els_id=S0021925820579325&rfr_iscdi=true |